In an unusual rebuke, shareholders of generic drug giant Mylan rejected the company’s executive pay practices at Thursday’s annual meeting but re-elected directors, despite the urging of large institutional investors and proxy advisory firms to oust them.
The nonbinding vote on pay was largely symbolic but reflected growing dissatisfaction over multimillion-dollar compensation packages that included nearly $100 million for chairman Robert Coury in 2016.
“For a company of this size, it’s pretty extraordinary to have a majority of shareholders vote against executive pay,” said Rosanna Landis Weaver, program manager at As You Sow, a nonprofit foundation in California whose mission is to promote corporate social responsibility through shareholder advocacy. “Shareholders are not pleased.”
Just 1 percent of pay plans at public companies have been voted down so far this year, according to compensation consultant Semler Brossy. Since 2011, public companies have been required to hold so-called say-on-pay votes allowing shareholders to voice their approval or disapproval of executive compensation every one, two or three years.
Mylan issued a statement Thursday saying the board’s compensation committee would “carefully consider these results, as well as future shareholder input ... in designing our compensation programs going forward.” Mylan did not respond to emails seeking further comment.
Mylan shareholders also rejected the company’s pay plan in 2012.
Read More
The vote against the pay plan on Thursday had been recommended earlier this month by three prominent companies that advise institutional investors on how to vote at shareholder meetings.
But the advisers had also recommended shareholders vote against the election of some or all of Mylan’s 10 incumbent directors, and investors did not take that advice.
Mylan’s practices have been under a stepped-up level of scrutiny since last year, when outrage over escalating prices for the company’s Epipen allergy treatment sparked government investigations amid accusations of price gouging. Mylan responded by introducing a half-price generic version in December.
Fallout over EpiPen price increases of nearly 500 percent in recent years contributed to a 29 percent drop in Mylan’s stock price last year.
Mylan’s annual meeting was held Thursday in Amsterdam, The Netherlands, where the company reincorporated in 2015 to cut its tax bill. The drugmaker continues to be run from executive offices in Cecil.
Concern over tax credits
Even as Mylan overcame the challenge to its board members, the company was also facing criticism of its use of clean coal tax credits to lower its taxes. Reuters reported this week that Mylan used federal tax credits from a clean coal program Congress enacted in 2004 to reduce its corporate tax bill by more than $100 million in both 2016 and 2015 and by about $95 million in 2014.
The news agency said Mylan confirmed those estimates, which were based on disclosures in the company’s annual reports.
While companies have a duty to shareholders to pay as little in taxes as legally possible, one coalition of union and other left-leaning groups that believe businesses should pay more taxes took issue with Mylan’s use of the coal credits.
Americans for Tax Fairness said Mylan took advantage of the tax loophole at the same time it was overcharging consumers and government health programs for its EpiPen.
“This is an outrageous example of how rigged the tax system is,” the organization said in an emailed statement. “If we’re going to have real tax reform, we need to close these special loopholes to make corporations like Mylan and the wealthy pay their fair share of taxes.”
The clean coal program provides a tax credit to companies that refine coal so that it emits less harmful emissions when it is burned. The credit was $6.81 for every ton of refined coal a provider produced last year. It rose to $6.91 per ton this year.
Mylan has 99 percent ownership interests in five companies that produce refined coal, Reuters reported.
Mylan’s 2016 annual report, filed with the Securities and Exchange Commission in March, indicates the tax credits were among the factors that allowed the company to record an income tax benefit of $358.3 million last year. Mylan said that resulted in an effective tax rate for 2016 of -294.4 percent.
In 2015, the company recorded a tax expense of $67.7 million, which translates into an effective tax rate of 7.4 percent, Mylan disclosed.
The U.S. corporate income tax rate is 35 percent. Many companies pay significantly less because of losses in prior years, tax credits and other provisions of the tax code that permit them to reduce their income tax liability.
Mylan told Reuters it first invested in the tax credit program in 2011 and that credits generated in 2012 and 2013 were less than half of those generated in subsequent years.
“This program is used by a number of other large public companies across various sectors,” Mylan said in a statement issued to the news agency.
Reuters identified Arthur J. Gallagher, Waste Management and WW Grainger as other companies that are involved in the refined coal tax credit program.
Waiting for final vote totals
Meanwhile, investors were waiting to see the final vote totals from Thursday’s shareholder meetings.
Ms. Weaver noted that regulations require Mylan to release the information in a filing with the SEC.
“It will be very interesting to see the votes,” she said. “If [directors] passed by a small margin, it’s a ringing indictment of the company.”
New York City Comptroller Scott Stringer, one of four large pension plan representatives who led a campaign to remove several incumbent board members, including Mr. Coury, issued a statement Thursday noting that, under Mylan’s rules, nominees could have been elected with as little as 34 percent of the votes cast.
“This company massively hiked prices on life-saving drugs, allegedly overcharged the government for its products, and allowed excessive executive pay to go unchecked — all ultimately fundamental failures of board oversight,” he said.
Patricia Sabatini: psabatini@post-gazette.com or 412-263-3066. Len Boselovic: lboselovic@post-gazette.com or 412-263-1941.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.